Artiva Biotherapeutics Inc Dossier
Qualitative Analysis
Business overview
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is a clinical-stage biotechnology company focused on developing off-the-shelf, allogeneic natural killer (NK) cell therapies for patients suffering from devastating autoimmune diseases and cancers. The company's lead product candidate is AlloNK (also known as AB-101), a non-genetically modified, cryopreserved NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with monoclonal antibodies. Artiva's pipeline also includes CAR-NK candidates such as AB-201 (targeting HER2-positive solid tumors) and AB-205 (targeting CD5-positive hematological malignancies). The company operates its own clinical-scale cGMP manufacturing facility in San Diego, California, alongside strategic manufacturing partnerships.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing and advancing AlloNK (AB-101) as a lead clinical program for refractory rheumatoid arthritis, focusing on outpatient feasibility and deep B-cell depletion in community settings.
Expected impact: Establish AlloNK as a first-in-class, outpatient-administered, community-compatible deep B-cell depleting therapy for refractory RA.
Expanding cGMP manufacturing capacity through a strategic partnership with GC Cell and investments in an in-house San Diego facility, alongside cold chain logistics to support product distribution.
Expected impact: Ensure scalable, off-the-shelf supply of cryopreserved NK cell therapies to support late-stage clinical trials and potential commercial launch.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Artiva exclusive worldwide rights (excluding Asia, Australia, and New Zealand) to GC Cell's NK cell manufacturing technology and programs, which form the foundation of Artiva's AlloNK platform.
Terms: Artiva was spun out of GC Cell in 2019 under this strategic agreement.
Jointly developing, manufacturing, and commercializing a combination therapy comprising Affimed's Innate Cell Engager AFM13 and Artiva's AB-101 (AlloNK) for CD30-positive lymphoma.
Terms: Co-exclusive basis in the US. Affimed leads regulatory activities and funds clinical study costs through Phase 2, while Artiva is responsible for the costs of supplying AB-101 and IL-2.